COMPASSION‑16 Phase III results show cadonilimab combined with chemotherapy, with or without bevacizumab, improves outcomes as first‑line treatment for advanced cervical cancer, the sponsors reported. The trial compared cadonilimab plus standard chemotherapy regimens against control arms and found clinically meaningful efficacy signals that could change first‑line practice in a disease with limited options. Cadonilimab is a bispecific PD‑1/CTLA‑4 targeting agent developed in China; the Phase III readout provides a regulatory and commercial inflection point for its developers and for global treatment guidelines. The data will shape regulatory filings, potential market access in regions with high cervical cancer burden, and competitive positioning against other immunotherapy combinations. The detailed safety profile and subgroup analyses will determine adoption and use with anti‑angiogenic agents such as bevacizumab.